# Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

> **NCT05408312** · PHASE1 · COMPLETED · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 234 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** Experimental Vaccine 1
- **BIOLOGICAL:** Experimental Vaccine 2
- **BIOLOGICAL:** Experimental Vaccine 3
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05408312
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-18
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05408312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05408312, "Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05408312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*